NCL Method GTA-14
Hep G2 Hepatocarcinoma Homogeneous Apoptosis Assay
Listed in Datasets | publication by group NCL Protocols
Version 1.0 - published on 04 May 2020 doi:10.17917/BPA7-XK19 - cite this Last public release: 2.0
Licensed under these terms
Description
This protocol describes the monitoring of nanoparticle treated human hepatocarcinoma cells (HepG2) for apoptosis, as part of the in vitro NCL preclinical characterization cascade (1, 2). The protocol utilizes a fluorescent method to measure Caspase-3/7 activation. This is a homogeneous assay that does not require cell isolation, as required for HepG2 Hepatocarcinoma Apoptosis Assay (NCL Method GTA-6).
Content List
- NCL_Method_GTA-14.pdf(PDF | 333 KB)
Cite this work
Researchers should cite this work as follows:
- Stephan Stern, Barry Neun (2020). NCL Method GTA-14. NCI Hub. doi:10.17917/BPA7-XK19
Tags
NCL Protocols
This publication belongs to the NCL Protocols group.
When watching a publication, you will be notified when a new version is released.